[
  {
    "ts": null,
    "headline": "Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy",
    "summary": "Physician Interview Now AvailableKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now availab",
    "url": "https://finnhub.io/api/news?id=dcb65bc76d6cb3278fae4f54093e84fb9b0afda3c577a60dfd478935e3e06f84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772111940,
      "headline": "Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy",
      "id": 139232793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HSIC",
      "source": "Yahoo",
      "summary": "Physician Interview Now AvailableKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now availab",
      "url": "https://finnhub.io/api/news?id=dcb65bc76d6cb3278fae4f54093e84fb9b0afda3c577a60dfd478935e3e06f84"
    }
  },
  {
    "ts": null,
    "headline": "Biomerica Announces Responder Analysis Results From Ongoing Real-World Study Of inFoods IBS",
    "summary": "Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company&#39;s peer-reviewed",
    "url": "https://finnhub.io/api/news?id=6ee0619f593f31b5d0117ab0bd155c4366669d69aad00a6f77c2456a439ffddb",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772097670,
      "headline": "Biomerica Announces Responder Analysis Results From Ongoing Real-World Study Of inFoods IBS",
      "id": 139231732,
      "image": "",
      "related": "HSIC",
      "source": "Benzinga",
      "summary": "Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company&#39;s peer-reviewed",
      "url": "https://finnhub.io/api/news?id=6ee0619f593f31b5d0117ab0bd155c4366669d69aad00a6f77c2456a439ffddb"
    }
  },
  {
    "ts": null,
    "headline": "How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation",
    "summary": "Henry Schein’s assessed fair value in the model has been nudged from US$78.14 to US$83.21, signaling a slightly higher valuation range under the latest assumptions. That shift lines up with recent Street research, where several firms have lifted their price targets into the US$87 to US$100 band as sentiment around dental demand and organic growth improves. Read on to see what is driving this evolving narrative and how you can track the key factors analysts are watching. Analyst Price Targets...",
    "url": "https://finnhub.io/api/news?id=f29148f20e2a2730dafa6e31b22dadcbd99618a2b5245783cbfb843b90178904",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772089966,
      "headline": "How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation",
      "id": 139229657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HSIC",
      "source": "Yahoo",
      "summary": "Henry Schein’s assessed fair value in the model has been nudged from US$78.14 to US$83.21, signaling a slightly higher valuation range under the latest assumptions. That shift lines up with recent Street research, where several firms have lifted their price targets into the US$87 to US$100 band as sentiment around dental demand and organic growth improves. Read on to see what is driving this evolving narrative and how you can track the key factors analysts are watching. Analyst Price Targets...",
      "url": "https://finnhub.io/api/news?id=f29148f20e2a2730dafa6e31b22dadcbd99618a2b5245783cbfb843b90178904"
    }
  }
]